CELULARITY INC. news, videos and press releases
For more news please use our advanced search feature.
CELULARITY INC. - More news...
CELULARITY INC. - More news...
- Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
- Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
- Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
- MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
- Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
- Celularity Inc. Announces Receipt of Nasdaq Notification
- Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
- Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
- Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
- Celularity Provides Corporate Update
- Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
- Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
- Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
- Celularity Appoints Richard J. Berman to its Board of Directors
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023
- Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
- Celularity Inc. to Host Investor and Analyst Research & Development Day
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
- Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
- Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
- Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
- Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
- Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
- Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
- Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
